Non-small-cell lung carcinoma

KIYATEC to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

Retrieved on: 
Monday, March 21, 2022

KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time.

Key Points: 
  • KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced that CEO Matt Gevaert, Ph.D., will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022, at 1:30 PM Eastern Time.
  • KIYATECs participation includes virtual one-on-one meetings with investors during the two-day event which begins Tuesday, March 22nd.
  • Leveraging its innovative 3D cell culture technology platform for both clinical and pre-clinical use, KIYATEC recently introduced its first commercial assay in the US, 3D Predict Glioma.
  • Recently, KIYATEC began a facilities expansion to support the Companys five-year growth plans to increase laboratory capacity and accelerate product development.

KIYATEC Announces Key Appointments in Market Access & Reimbursement and Business Development Roles

Retrieved on: 
Monday, March 21, 2022

KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced two key appointments as the Company builds utilization of clinical 3D Predict assays and grows its pharmaceutical services portfolio for KIYA-PREDICT.

Key Points: 
  • KIYATEC , the leader in clinically correlated, published functional precision oncology technology today announced two key appointments as the Company builds utilization of clinical 3D Predict assays and grows its pharmaceutical services portfolio for KIYA-PREDICT.
  • KIYATEC is pleased to welcome Bruce Yeager as Vice President Market Access & Reimbursement effective March 21, 2022, and Steven Holshouser, Ph.D., as Director, Business Development, effective March 8, 2022.
  • Chief Executive Officer Matt Gevaert, Ph.D., said, We are pleased to welcome both Bruce and Steven to our growing team of experienced leaders in their respective fields.
  • KIYATEC is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform.

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLC

Retrieved on: 
Thursday, February 10, 2022

Under the agreement, the partners plan to jointly validate and register Genetron Healths approved NGS-based 8-gene Lung Cancer Assay (Tissue) as CDx for ORPATHYS.

Key Points: 
  • Under the agreement, the partners plan to jointly validate and register Genetron Healths approved NGS-based 8-gene Lung Cancer Assay (Tissue) as CDx for ORPATHYS.
  • Following a priority review, ORPATHYS was granted drug registration conditional approval by the NMPA in China in June 2021.
  • CDx test is becoming a valuable tool for the use of ORPATHYS in the clinical setting for NSCLC patients harboring MET exon 14 skipping alterations.
  • We look forward to developing this diagnostic solution with Genetron Health to allow more patients to benefit from this innovative therapy.

Pfizer Announces New Chief Development Officer

Retrieved on: 
Tuesday, February 1, 2022

Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022.
  • Dr. Pao will be a member of Pfizers Executive Leadership Team reporting to Chairman and Chief Executive Officer, Albert Bourla.
  • Dr. Pao succeeds Rod MacKenzie who recently announced his intent to retire after a 35-year career at Pfizer.
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

TScan Outlines 2022 Priorities as Programs Enter Clinic

Retrieved on: 
Monday, January 10, 2022

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, announced that the Company plans to begin its first clinical trials this year. As forecasted, in December 2021 TScan filed INDs for TSC-100 and TSC-101, its TCR-T programs to prevent relapse in leukemia patients following hematopoietic cell transplants. In addition, TScan is outlining here its priorities for 2022 across its pipeline of solid and liquid tumors as well as infectious disease.

Key Points: 
  • In addition, TScan is outlining here its priorities for 2022 across its pipeline of solid and liquid tumors as well as infectious disease.
  • We are excited to enter the clinic this year with the first two TCR-T programs from our proprietary TCR discovery and development platform.
  • Over the course of 2021 TScan made transformative strides in building the scientific, manufacturing and regulatory operations to support multiple clinical programs.
  • TScan plans to present initial preclinical data on the TSC-2xx series at a medical meeting in the first half of 2022.

AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, January 4, 2022

Despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths in both men and women in the U.S. and throughout the world.

Key Points: 
  • Despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths in both men and women in the U.S. and throughout the world.
  • "Today's announcement marks an important step in our mission to advance new oncology treatments across tumor types to improve standards of care for patients with cancer."
  • The primary endpoint is overall response rate (ORR) per central review in patients with 12 weeks follow-up.
  • In addition, it will be further evaluated as monotherapy in patients with previously treated c-Met overexpressing NSCLC in the randomized Phase 3 study TeliMET NSCLC-01 (Study M18-868).

Global Lung Cancer Diagnostics Market (2021 to 2027) - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021

The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope.

Key Points: 
  • The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope.
  • Non-small cell lung cancer (NSCLC) is the unique form of cancer and accounts for 85% of lung cancer cases.
  • As per our analysis, non-small cell lung cancer dominates small cell lung cancer around the world.
  • Consequently, helping to track treatment progress and capture the highest market share in the Lung Cancer Diagnostics Market.

Genetron Health’s Social Contribution Campaign to Make Precision Medicine More Accessible

Retrieved on: 
Monday, December 13, 2021

As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.

Key Points: 
  • As the sole corporate donor, Genetron Health will provide free genetic testing services (using its 8-gene lung cancer assay) for 10,000 Chinese lung cancer patients.
  • Meanwhile, identifying rare driver gene mutations is also crucial to the diagnosis and treatment of lung cancer.
  • This particular project will leverage 8-gene lung cancer assays and testing services provided by Genetron Health.
  • We hope that in the future, there will be more companies that are as enthusiastic about public welfare as Genetron Health is, and are committed to improving precision medicine accessibility.

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, December 8, 2021

The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide.

Key Points: 
  • The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide.
  • Approximately 560 subjects will be randomized in a 2:1 ratio to receive cosibelimab in combination with chemotherapy or chemotherapy alone.
  • Lung cancer is the most common cancer worldwide according to the World Health Organization, accounting for more than 2 million new cases diagnosed each year.
  • Lung cancer is by far the leading cause of cancer death among both men and women, making up almost 25% of all cancer deaths.

Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization

Retrieved on: 
Tuesday, November 23, 2021

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.
  • New results specifically focus on the characterization of stage 1 lung cancer nodules, using Medians proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
  • Lung cancer is the number one cancer killer globally, causing an estimate of 1.8m deaths, accounting for 18% of all cancer deaths in 20202.
  • A noteworthy International Early Lung Cancer Action Program (I-ELCAP) cohort study of stage 1 cancer patients4 revealed an excellent 15-year LCS survival of 92% which again serves to show how critical early stage diagnosis via lung cancer screening remains.